Takeda Pharmaceutical are launching an open innovation initiative inviting researchers to submit their proposals addressing novel technologies and approaches related to immuno‑oncology of tumours. One‑year projects will be funded up to JPY 10,000,000 or equivalent amount, including indirect costs.
REF#3 Induction of anti‑tumour effects in ‘cold’ tumours insensitive to immune checkpoint inhibitors.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.